Biomarker of Lung Disease in African Americans

项目总结/摘要 慢性阻塞性肺疾病（COPD）是美国第三大死亡原因1，2。虽然 COPD主要发生在吸烟者中，目前尚不清楚为什么只有少数吸烟者（约20-40%）发生COPD 慢性气流限制或远端气隙破坏（肺气肿）。鉴定分子图谱， 目前或以前的吸烟者谁可能进展是一个关键的一步，了解发病机制， COPD和肺气肿。很少有出版物描述COPD生物标志物， 包括大量非裔美国人的表型队列。这项研究将利用大型NIH- 支持的队列（COPDGene、SPIROMICS和MESA-Lung）具有大量充分表征的 患有COPD或有COPD风险的非裔美国人受试者。由于受试者储存了血浆， 经过7-10年的广泛临床、生理和影像学随访，我们可以非常经济有效地应用 蛋白质组学方法此外，由于队列有其他有价值的组学数据，我们可以整合 蛋白质组学研究与全基因组测序和其他先进的分子研究，如基因组学。 这些知识可能有助于开发新的诊断测试和治疗方法，用于早期预防和治疗 COPD，并将确定任何标志物，具体到吸烟相关的肺部疾病在非洲裔美国人。

PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the US1,2. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation or destruction of distal airspaces (emphysema). Identification molecular profiles from current or former smokers who are likely to progress is a crucial step in understanding the pathogenesis of COPD and emphysema. There are very few publications that describe COPD biomarkers in large, well phenotyped cohorts that include a significant number of African Americans. This study will leverage large NIH- supported cohorts (COPDGene, SPIROMICS, and MESA-Lung) that have large number of well-characterized African Americans subjects with or at risk for COPD. Since the subjects have stored plasma and have been followed for 7-10 years with extensive clinical, physiologic, and imaging, we can very cost-effectively apply a proteomic approach. Furthermore, because the cohorts have other valuable Omics data, we can integrate the proteomic findings with whole genome sequencing and other advanced molecular studies such as genomics. This knowledge may help develop novel diagnostic tests and therapies for early prevention and treatment of COPD and will identify any markers that are specific to smoking-related lung disease in African Americans.